Annovis Bio (ANVS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$14.8M

Net income growth (year over year)

−138.27%

Net margin

—

Return on equity

−703.68%

EPS (trailing twelve months)

−$1.75

Book value per share

−$0.10

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

119.31%

Payout ratio

—

Dividend yield

—

Company profile

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

• How do I buy stock in Annovis Bio (ANVS)?

  ANVS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.